

BeiGene, Ltd.  
Form 8-K  
January 02, 2018

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): January 2, 2018

**BEIGENE, LTD.**

(Exact Name of Registrant as Specified in Charter)

**Cayman Islands**

(State or Other Jurisdiction of  
Incorporation)

**001-37686**

(Commission File Number)

**98-1209416**

(I.R.S. Employer Identification  
Number)

**c/o Mourant Ozannes Corporate Services (Cayman)  
Limited**

**94 Solaris Avenue, Camana Bay  
Grand Cayman KY1-1108  
Cayman Islands**

(Address of Principal Executive Offices) (Zip Code)

**+1 (345) 949 4123**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

[  
]

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ X ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ X ]

---

**Item 8.01. Other Events.**

On January 2, 2018, BeiGene, Ltd. (the “Company”) issued a press release announcing that the first patient was dosed in a global Phase 3 clinical trial of tislelizumab (BGB-A317), an investigational anti-PD-1 antibody, in patients with previously untreated advanced hepatocellular carcinoma. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	Press Release issued on January 2, 2018

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BEIGENE, LTD.**

Date: January 2, 2018

By: /s/ Scott A. Samuels  
Scott A. Samuels  
Senior Vice President, General Counsel

---

**EXHIBIT INDEX**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
<u>99.1</u>	Press Release issued on January 2, 2018